Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023676871> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3023676871 endingPage "S76" @default.
- W3023676871 startingPage "S76" @default.
- W3023676871 abstract "Opioids are commonly prescribed for chronic cancer pain, but concern remains regarding the safety of opioids for chronic non-malignant pain. Currently available morphine sulfate formulations are associated with side effects such as constipation, nausea/vomiting, somnolence, dizziness, pruritus, and headache. A need exists for opioids with improved safety and tolerability to manage chronic non-malignant pain. The aim was to establish the safety and tolerability of Kadian in the treatment of chronic non-malignant pain. A community-based, prospective, randomized, open-label, blinded endpoint design was employed. Investigators randomized 1418 patients with chronic, non-malignant, moderate/severe pain and a baseline visual numeric scale (VNS) pain score ≥4 to AM or PM QD dosing with Kadian for 4 weeks. All patients were previously treated for pain unsuccessfully. Adverse events were recorded throughout the study. A broad range of patients was included with a wide range of chronic non-malignant pain conditions, with 54.1% of patients reporting a total of 2526 concomitant medications. 563 patients experienced 1066 drug-related adverse events. The most frequent were constipation (12.9%), nausea (11.2%), and somnolence (4.9%); these rates are lower than those seen in other long-acting opioids, which show constipation at 21-32%, nausea at 23-49%, and somnolence at 12-27%. 9.6% of patients (136/1418) withdrew from treatment due to adverse events compared to 15.4-29.5% seen using other long-acting opioids. There were no differences in type, frequency, or severity of adverse events with respect to gender or race. The KRONUS-MSP trial results demonstrate that Kadian was: associated with lower frequencies of typical opioid-related adverse events, irrespective of gender or race; was associated with few serious adverse events; and was safe when used with many concomitant medications. The low rate of discontinuation establishes the tolerability of Kadian and supports its use for long-term management of patients with chronic non-malignant pain." @default.
- W3023676871 created "2020-05-13" @default.
- W3023676871 creator A5027521713 @default.
- W3023676871 creator A5050198112 @default.
- W3023676871 creator A5054775052 @default.
- W3023676871 creator A5090157053 @default.
- W3023676871 date "2004-04-01" @default.
- W3023676871 modified "2023-09-26" @default.
- W3023676871 title "Opioids in non-cancer pain" @default.
- W3023676871 doi "https://doi.org/10.1016/j.jpain.2004.02.272" @default.
- W3023676871 hasPublicationYear "2004" @default.
- W3023676871 type Work @default.
- W3023676871 sameAs 3023676871 @default.
- W3023676871 citedByCount "0" @default.
- W3023676871 crossrefType "journal-article" @default.
- W3023676871 hasAuthorship W3023676871A5027521713 @default.
- W3023676871 hasAuthorship W3023676871A5050198112 @default.
- W3023676871 hasAuthorship W3023676871A5054775052 @default.
- W3023676871 hasAuthorship W3023676871A5090157053 @default.
- W3023676871 hasBestOaLocation W30236768711 @default.
- W3023676871 hasConcept C121608353 @default.
- W3023676871 hasConcept C126322002 @default.
- W3023676871 hasConcept C1862650 @default.
- W3023676871 hasConcept C197934379 @default.
- W3023676871 hasConcept C2778375690 @default.
- W3023676871 hasConcept C2778904085 @default.
- W3023676871 hasConcept C2779034229 @default.
- W3023676871 hasConcept C2779384505 @default.
- W3023676871 hasConcept C2780580376 @default.
- W3023676871 hasConcept C2780852908 @default.
- W3023676871 hasConcept C2781112942 @default.
- W3023676871 hasConcept C2781118164 @default.
- W3023676871 hasConcept C42219234 @default.
- W3023676871 hasConcept C71924100 @default.
- W3023676871 hasConceptScore W3023676871C121608353 @default.
- W3023676871 hasConceptScore W3023676871C126322002 @default.
- W3023676871 hasConceptScore W3023676871C1862650 @default.
- W3023676871 hasConceptScore W3023676871C197934379 @default.
- W3023676871 hasConceptScore W3023676871C2778375690 @default.
- W3023676871 hasConceptScore W3023676871C2778904085 @default.
- W3023676871 hasConceptScore W3023676871C2779034229 @default.
- W3023676871 hasConceptScore W3023676871C2779384505 @default.
- W3023676871 hasConceptScore W3023676871C2780580376 @default.
- W3023676871 hasConceptScore W3023676871C2780852908 @default.
- W3023676871 hasConceptScore W3023676871C2781112942 @default.
- W3023676871 hasConceptScore W3023676871C2781118164 @default.
- W3023676871 hasConceptScore W3023676871C42219234 @default.
- W3023676871 hasConceptScore W3023676871C71924100 @default.
- W3023676871 hasIssue "3" @default.
- W3023676871 hasLocation W30236768711 @default.
- W3023676871 hasOpenAccess W3023676871 @default.
- W3023676871 hasPrimaryLocation W30236768711 @default.
- W3023676871 hasRelatedWork W2350806868 @default.
- W3023676871 hasRelatedWork W2358657645 @default.
- W3023676871 hasRelatedWork W2362740208 @default.
- W3023676871 hasRelatedWork W2364563209 @default.
- W3023676871 hasRelatedWork W2371474094 @default.
- W3023676871 hasRelatedWork W2372689149 @default.
- W3023676871 hasRelatedWork W2373112319 @default.
- W3023676871 hasRelatedWork W2374190337 @default.
- W3023676871 hasRelatedWork W2375674127 @default.
- W3023676871 hasRelatedWork W4220940719 @default.
- W3023676871 hasVolume "5" @default.
- W3023676871 isParatext "false" @default.
- W3023676871 isRetracted "false" @default.
- W3023676871 magId "3023676871" @default.
- W3023676871 workType "article" @default.